Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polychlorinated Biphenyls | 11 | 2022 | 40 | 4.490 |
Why?
|
| Environmental Pollutants | 9 | 2022 | 166 | 3.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 592 | 1.910 |
Why?
|
| Metabolic Diseases | 2 | 2023 | 32 | 1.680 |
Why?
|
| Environmental Exposure | 3 | 2022 | 207 | 1.050 |
Why?
|
| Gene Expression | 5 | 2017 | 639 | 0.930 |
Why?
|
| Fatty Liver | 1 | 2023 | 56 | 0.910 |
Why?
|
| Dyslipidemias | 1 | 2022 | 42 | 0.860 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2022 | 17 | 0.850 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 600 | 0.850 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 195 | 0.790 |
Why?
|
| Pakistan | 3 | 2022 | 21 | 0.590 |
Why?
|
| Slovakia | 5 | 2022 | 7 | 0.570 |
Why?
|
| Chronic Disease | 1 | 2017 | 469 | 0.500 |
Why?
|
| Endocrine Disruptors | 1 | 2014 | 38 | 0.470 |
Why?
|
| Mutagens | 2 | 2010 | 66 | 0.460 |
Why?
|
| Humans | 19 | 2023 | 34853 | 0.450 |
Why?
|
| Cytochrome P-450 CYP2D6 | 2 | 2022 | 17 | 0.440 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 881 | 0.400 |
Why?
|
| Pilot Projects | 2 | 2023 | 628 | 0.360 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 968 | 0.360 |
Why?
|
| District of Columbia | 2 | 2022 | 68 | 0.350 |
Why?
|
| Neoplasms | 1 | 2017 | 1033 | 0.320 |
Why?
|
| Child | 3 | 2022 | 2875 | 0.290 |
Why?
|
| Protein Biosynthesis | 1 | 2007 | 123 | 0.290 |
Why?
|
| Obesity | 1 | 2014 | 965 | 0.270 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2015 | 224 | 0.250 |
Why?
|
| Liver | 1 | 2007 | 447 | 0.250 |
Why?
|
| Nerve Tissue Proteins | 2 | 2023 | 338 | 0.240 |
Why?
|
| PPAR alpha | 1 | 2022 | 42 | 0.220 |
Why?
|
| Triglycerides | 1 | 2022 | 129 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 298 | 0.210 |
Why?
|
| Apolipoproteins E | 1 | 2022 | 129 | 0.210 |
Why?
|
| Apoptosis | 3 | 2010 | 1317 | 0.200 |
Why?
|
| Cholesterol | 1 | 2022 | 194 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 34 | 0.200 |
Why?
|
| Guanine | 1 | 2021 | 45 | 0.200 |
Why?
|
| Genomics | 1 | 2022 | 201 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 180 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2022 | 1318 | 0.200 |
Why?
|
| Lipids | 1 | 2022 | 222 | 0.200 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2020 | 14 | 0.190 |
Why?
|
| Halogenation | 1 | 2020 | 19 | 0.190 |
Why?
|
| DNA Methylation | 1 | 2023 | 301 | 0.190 |
Why?
|
| Blood Glucose | 1 | 2022 | 333 | 0.190 |
Why?
|
| ras Proteins | 1 | 2020 | 49 | 0.190 |
Why?
|
| Hepatocytes | 2 | 2010 | 74 | 0.190 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2019 | 3 | 0.180 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2019 | 5 | 0.180 |
Why?
|
| DNA Fragmentation | 2 | 2010 | 91 | 0.170 |
Why?
|
| Prostatic Neoplasms | 2 | 2023 | 794 | 0.170 |
Why?
|
| Printing | 1 | 2017 | 7 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2023 | 781 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2017 | 1422 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2017 | 1802 | 0.150 |
Why?
|
| Rural Population | 1 | 2018 | 253 | 0.140 |
Why?
|
| Cell Survival | 2 | 2010 | 818 | 0.140 |
Why?
|
| Adolescent | 2 | 2017 | 5035 | 0.140 |
Why?
|
| Cell Movement | 1 | 2019 | 545 | 0.140 |
Why?
|
| Sex Factors | 1 | 2018 | 859 | 0.130 |
Why?
|
| Incidence | 1 | 2017 | 882 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1003 | 0.130 |
Why?
|
| Male | 6 | 2023 | 18870 | 0.120 |
Why?
|
| Prevalence | 1 | 2018 | 1425 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 455 | 0.110 |
Why?
|
| United States | 1 | 2022 | 3894 | 0.110 |
Why?
|
| Female | 6 | 2021 | 19873 | 0.110 |
Why?
|
| Hexachlorobenzene | 1 | 2011 | 3 | 0.110 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2011 | 6 | 0.110 |
Why?
|
| Hazardous Substances | 1 | 2011 | 18 | 0.110 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1490 | 0.100 |
Why?
|
| Trypan Blue | 1 | 2010 | 2 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 47 | 0.100 |
Why?
|
| Lethal Dose 50 | 1 | 2010 | 30 | 0.100 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 40 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2561 | 0.100 |
Why?
|
| Cell Line | 2 | 2010 | 1289 | 0.090 |
Why?
|
| Immunoblotting | 2 | 2007 | 170 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 4012 | 0.090 |
Why?
|
| Cell Death | 1 | 2010 | 260 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 416 | 0.080 |
Why?
|
| Middle Aged | 2 | 2021 | 9642 | 0.080 |
Why?
|
| Animals | 2 | 2020 | 14307 | 0.070 |
Why?
|
| Adult | 2 | 2021 | 11034 | 0.070 |
Why?
|
| Aged | 1 | 2018 | 6448 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2007 | 351 | 0.070 |
Why?
|
| Time Factors | 2 | 2007 | 1681 | 0.070 |
Why?
|
| Phosphorylcholine | 1 | 2004 | 8 | 0.060 |
Why?
|
| Staurosporine | 1 | 2004 | 35 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 874 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2004 | 171 | 0.060 |
Why?
|
| CpG Islands | 1 | 2023 | 91 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 2128 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 178 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2023 | 287 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2021 | 37 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2011 | 61 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 336 | 0.050 |
Why?
|
| Histones | 1 | 2021 | 177 | 0.050 |
Why?
|
| Methylcholanthrene | 1 | 2019 | 4 | 0.040 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2019 | 5 | 0.040 |
Why?
|
| Body Weight | 1 | 2021 | 404 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 1152 | 0.040 |
Why?
|
| Actins | 1 | 2019 | 142 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2019 | 1149 | 0.030 |
Why?
|
| Disease | 1 | 2011 | 18 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 115 | 0.020 |
Why?
|
| Paraquat | 1 | 2010 | 20 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 43 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 198 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 240 | 0.020 |
Why?
|
| RNA | 1 | 2011 | 234 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 727 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 605 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 5668 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 22 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 18 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2004 | 309 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 396 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 834 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 984 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 756 | 0.010 |
Why?
|